ReviewOncology letters2025
The role of NR2F2 in cancer (Review).
Review in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MPOInt: An Epigenetics-Driven Workflow for Integrative Multi-Level Proteomics.Journal of proteome research · 2026Article
- NR2F2/AGAP2 axis: regulating lipid synthesis to drive AML progression via AMPKα/ACC pathway.Cellular oncology (Dordrecht, Netherlands) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence and mortality rates of tumors continue to show an annual upward trend. Since its discovery in 1986, nuclear receptor subfamily 2, group F, member 2 (NR2F2) has been shown to serve a key role in the transcriptional regulation of various genes. Furthermore, NR2F2 has a notable impact on the progression of tumors; however, its role in tumor progression it not yet fully understood. Multi-omics can illuminate the paradoxical roles of NR2F2 across various malignancies, where it functions as either an oncogenic driver or tumor suppressor in a context-dependent manner. The present review discusses the determinant influence of NR2F2 in modulating disease advancement and mechanisms in heterogeneous types of cancer, including its effects on tumor proliferation, apoptosis and epithelial-mesenchymal transition. The aim was to assess the role and mechanisms of NR2F2 in various tumors, identify its clinical utility in targeted cancer therapy and thereby provide a novel therapeutic option for overcoming cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.